Trial Profile

A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bersacapavir (Primary) ; Entecavir (Primary) ; JNJ 73763989 (Primary) ; Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Peginterferon alfa-2a
Indications Hepatitis B
Focus Therapeutic Use
Acronyms INSIGHT
Sponsors Janssen Sciences Ireland UC

20 Feb 2024 This study has been completed in France, according to European Clinical Trials Database record.
08 Feb 2024 Status changed from active, no longer recruiting to completed.
02 Dec 2023 This trial has been completed in Belgium, according to the European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com